Next-Generation Lipid Nanoparticles for Precision Nucleic Acid Delivery

Patent Status

Patent Pending

Brief Description

Lipid nanoparticle (LNP) technology offers a powerful solution to the challenges of delivering free nucleic acids, providing protection against degradation, enhanced cellular uptake, and efficient intracellular delivery.

Researchers at UC Berkeley have developed a novel LNP platform capable of delivering multiple types of nucleic acids across different tissues, with demonstrated efficacy in in vivo mouse models. Its versatility, modularity, and gene-editing compatibility offer exciting potential for RNA therapeutics, vaccines, and next-generation genetic medicines.

The technology has been validated using CRISPR-Cas9 and guide RNA targeting the endogenous Tau locus. Given the role of Tau dysregulation and aggregation in Alzheimer's disease, this platform offers a promising new approach for investigating and potentially intervening in disease-associated pathways.

Combining versatile cargo delivery, tissue accessibility, and demonstrated in vivo performance, this technology has the potential to become a powerful platform for precision gene editing and therapeutic development.

Suggested uses

• therapeutic applications, particularly ones targeting the Tau locus (e.g., Alzheimers disease)

Advantages

• novel lipid formulation 
• demonstrated ability to deliver diverse nucleic acids across different tissues